Giada Sebastiani

Academic title(s): 

Associate Professor, Department of Medicine, McGill University

Giada Sebastiani
Contact Information

McGill University Health Centre

Royal Victoria Hospital Site

1001 Decarie Blvd, Montreal, QC H4A 3J1

Tel: (514) 843-1616

: Clinician Scientist at the Research Institute of McGill University Health Centre


Fellowship Training: 
  • Harvard Medical School, US
  • Royal Free Hospital, University College of London, UK
  • University of Bordeaux, France
  • Lady Davis Institute for Medical Research, McGill University
Areas of expertise: 

Liver fibrosis, Non-alcoholic fatty liver disease, non-invasive diagnostic tools (serum biomarkers, transient elastography), screening for liver disease in HIV+ patients and other at risk populations.


Dr Giada Sebastiani is a clinician-scientist and hepatologist. She is also an investigator at Research Institute of the McGill University Health Centre. Her work focuses on chronic liver diseases, fatty liver, HIV and comorbidities, non-invasive assessment of liver fibrosis by Fibroscan (a new ultrasound tool) and biomarkers. She is an author of 253 publications including 104 articles in peer-reviewed journals (32 as senior/solo author, 35 as first author), 158 conference papers and 13 book chapters, which have received 4228 citations (H index 34; Google Scholar, January 2020). She has built an international profile giving over 70 invited presentations in Europe, Asia, North America, and Africa. She was awarded the prestigious Clinical Research Salary Award from Fonds Recherche Sante Quebec (FRSQ). Other honors include: the honorary membership of the Romanian Association for the Study of the Liver; the Emerging Stars in Hepatology Award (Asian Pacific Association for the Study of the Liver, 2010); the Top 10 cited papers 2006-2008 Award by Journal of Hepatology - European Association for the Study of the Liver (EASL). She has secured research funds, with 7 peer-reviewed grants (CIHR, CIHR Canadian HIV Trials Network, Canadian Society of Transplantation, FRQS Reseau SIDA et maladies infectieuses) and several unrestrictive and competitive industry-sponsored grants. She is also a co-applicant in several CIHR funded grants, including 2 PanCanadian CIHR Team grants and a site investigator for eight global fatty liver trials with new antifibrotic agents.

Selected publications: 

Saroli Palumbo C, Restellini S, Chao CY, Aruljothy A, Lemieux C, Wild G, Afif W, Lakatos PL, Bitton A, Cocciolillo S, Ghali P, Bessissow T, Sebastiani G. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. Inflamm Bowel Dis 2019;25:124-133. doi: 10.1093/ibd/izy200.

Benmassaoud A, Nitulescu R, Pembroke T, Halme AS, Ghali P, Deschenes M, Wong P, Klein MB, Sebastiani G. Liver-related events in HIV-infected persons with occult cirrhosis. Clin Infect Dis 2018 Dec 18. doi: 10.1093/cid/ciy1082. [Epub ahead of print].

Benmassaoud A, Ghali P, Cox J, Wong P, Szabo J, Deschenes M, Osikowicz M, Lebouche B, Klein MB, Sebastiani G. Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection. PLoS One 2018, Jan 30;13(1):e0191985. doi: 10.1371/journal.pone.0191985.

Petta S, Sebastiani G, Bugianesi E, Viganò M, Wong VW, Berzigotti A, Fracanzani AL, Anstee QM, Marra F, Barbara M, Calvaruso V, Cammà C, Di Marco V, Craxì A, de Ledinghen V. Noninvasive Prediction of Esophageal Varices by Stiffness and Platelet in Nonalcoholic Fatty Liver Disease Cirrhosis. J Hepatol 2018;69:878-885. pii: S0168-8278(18)32065-8. doi: 10.1016/j.jhep.2018.05.019.

Pembroke T, Deschenes M, Lebouché B, Benmassaoud A, Sewitch M, Ghali P, Wong P, Halme A, Vuille-Lessard E, Pexos C, Klein MB, Sebastiani G. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV coinfected patients and is associated with liver fibrosis. J Hepatol 2017;67:801-808. doi: 10.1016/j.hep.2017.05.11.

Dulai P, Singh S, Patel J, Soni M, Younossi Z, Sebastiani G, Ekstedt M, Hagström H, Nasr P, Stal P, Wong V, Kechagias S, Hultcrantz R, Loomba R. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic Review and Meta-analysis. Hepatology 2017;65:1557-1565. doi: 10.1002/hep.29085.

Vuille-Lessard E, Lebouché B, Lennox L, Routy JP, Costiniuk C, Pexos C, Giannakis A, Szabo J, Klein MB, Sebastiani G. Nonalcoholic Fatty Liver Disease Diagnosed by Transient Elastography with Controlled Attenuation Parameter in Unselected HIV Mono-Infected Patients. AIDS 2016;30:2635-2643.

Bessissow T, Le NH, Rollet K, Afif W, Bitton A, Sebastiani G. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:1937-44. doi: 10.1097/MIB.0000000000000832.

Bhat M, Ghali P, Rollet-Kurhajec KC, Bhat A, Wong P, Deschenes M, Sebastiani G. Serum fibrosis biomarkers predict death and graft loss in liver transplantation recipients. Liver Transpl 2015;21:1383-94. doi: 10.1002/lt.24217.

Sebastiani G, Tempesta D, Fattovich G, Castera L, Halfon P, Bourliere M, Angeli P, Noventa F, Saggioro A, Alberti A. Prediction of oesophageal varices in hepatic cirrosi by using simple non-invasive markers: results of a multicenter, International study. J Hepatol 2010;53:630-8.

Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Guido M, Bourliere M, Noventa F, Alberti A. SAFE-biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009;49:1821-7.

MUHC, Royal Victoria Hospital
Back to top